Korean Drug Co. Ltd Total Liabilities
Korean Drug Co. Ltd total liabilities. Based on the latest financial reports, Korean Drug Co. Ltd (014570) has total liabilities worth ₩20.08 Billion KRW (≈ $13.61 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Korean Drug Co. Ltd to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Korean Drug Co. Ltd (2014–2025)
Total liabilities of Korean Drug Co. Ltd from 2014 to 2025. This chart illustrates how Korean Drug Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Korean Drug Co. Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
Korean Drug Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Korean Drug Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Rex Industry Bhd
KLSE:9946
|
Malaysia | RM22.39 Million |
|
CU Medical Systems Inc
KQ:115480
|
Korea | ₩39.99 Billion |
|
Pure Hydrogen Corporation Ltd
AU:PH2
|
Australia | AU$10.49 Million |
|
VACCITECH (SP.ADR)/1
F:2AB
|
Germany | €25.66 Million |
|
Aytu BioScience Inc
NASDAQ:AYTU
|
USA | $76.55 Million |
|
Zuleika Gold Ltd
AU:ZAG
|
Australia | AU$2.06 Million |
|
Food and Drinks Public Company Limited
BK:F&D
|
Thailand | ฿519.07 Million |
|
MegaMD Co. Ltd
KQ:133750
|
Korea | ₩16.86 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Korean Drug Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Korean Drug Co. Ltd.
Liquidity & Leverage Metrics
Korean Drug Co. Ltd Total Liabilities Ratios Explained
Korean Drug Co. Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Korean Drug Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Korean Drug Co. Ltd (2014–2025)
The table below shows the annual total liabilities of Korean Drug Co. Ltd from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩11.25 Billion ≈ $7.62 Million |
+4.32% |
| 2024-12-31 | ₩10.78 Billion ≈ $7.31 Million |
-14.56% |
| 2023-12-31 | ₩12.62 Billion ≈ $8.55 Million |
+28.72% |
| 2022-12-31 | ₩9.80 Billion ≈ $6.64 Million |
-17.77% |
| 2021-12-31 | ₩11.92 Billion ≈ $8.08 Million |
-4.42% |
| 2020-12-31 | ₩12.47 Billion ≈ $8.45 Million |
+15.50% |
| 2019-12-31 | ₩10.80 Billion ≈ $7.32 Million |
+6.27% |
| 2018-12-31 | ₩10.16 Billion ≈ $6.89 Million |
+3.48% |
| 2017-12-31 | ₩9.82 Billion ≈ $6.66 Million |
+0.73% |
| 2016-12-31 | ₩9.75 Billion ≈ $6.61 Million |
+2.42% |
| 2015-12-31 | ₩9.52 Billion ≈ $6.45 Million |
-28.88% |
| 2014-12-31 | ₩13.38 Billion ≈ $9.07 Million |
-- |
About Korean Drug Co. Ltd
Korean Drug Co., Ltd. manufactures and sells medicines for treating various diseases in South Korea. The company offers Medicines for urinary tract disease, digestive system, circulatory system, psychonervous system, central nervous system, respiratory system, and skin and subcutaneous system; and antivirals, antibiotics, antifungals, antipyretic, analgesis, anti-inflammatory, and other products.… Read more